机译:用免疫球蛋白加上西科孢菌素预防川崎病患者冠状动脉异常的疗效预测,预测静脉内免疫球蛋白(KAICA)的风险增加:随机控制,开放标签,盲终点,阶段3 审判
Chiba Univ Grad Sch Med Chiba Japan;
Wakayama Med Univ Med Dept Pediat Wakayama Japan;
Chiba Univ Dept Publ Hlth Chiba Japan;
Chiba Univ Dept Pediat Chiba Japan;
Tokyo Womens Med Univ Yachiyo Med Ctr Dept Pediat Chiba Japan;
NTT Sapporo Med Ctr Dept Pediat Sapporo Hokkaido Japan;
Chiba Cardiovasc Ctr Dept Pediat Chiba Japan;
Oriono Clin Sakai Osaka Japan;
Japanese Red Cross Kumamoto Hosp Dept Pediat Kumamoto Japan;
Showa Univ Northern Yokohama Hosp Dept Pediat Yokohama Kanagawa Japan;
Hiroshima City Hiroshima Citizens Hosp Dept Pediat Cardiol Hiroshima Japan;
Natl Ctr Global Hlth &
Med Dept Pediat Tokyo Japan;
Kimitsu Chuo Hosp Dept Pediat Chiba Japan;
Kumamoto Reg Med Ctr Dept Pediat Kumamoto Japan;
Funabashi Municipal Med Ctr Dept Pediat Funabashi Chiba Japan;
Okinawa Prefectural Nanbu Med Ctr Dept Pediat Cardiol Okinawa Japan;
Nihon Univ Itabashi Hosp Dept Pediat Tokyo Japan;
Ehime Prefectural Cent Hosp Dept Pediat Matsuyama Ehime Japan;
Kagoshima City Hosp Dept Pediat Kagoshima Japan;
Takatsuki Gen Hosp Dept Pediat Osaka Japan;
Kawasaki Med Sch Hosp Dept Pediat Okayama Japan;
Natl Ctr Child Hlth &
Dev Dept Gen Pediat &
Interdisciplinary Med Tokyo Japan;
Toho Univ Dept Pediat Tokyo Japan;
Univ Toyama Grad Sch Med Dept Pediat Toyama Japan;
Hokkaido Univ Hosp Dept Pediat Sapporo Hokkaido Japan;
Ehime Univ Grad Sch Med Dept Reg Pediat &
Perinatol Matsuyama Ehime Japan;
Komatsu Municipal Hosp Dept Pediat Komatsu Ishikawa Japan;
Chiba Univ Hosp Clin Res Ctr Chiba Japan;
Chiba Univ Hosp Clin Res Ctr Chiba Japan;
Chiba Univ Hosp Clin Res Ctr Chiba Japan;
Chiba Univ Hosp Clin Res Ctr Chiba Japan;
Chiba Univ Hosp Clin Res Ctr Chiba Japan;
Chiba Univ Hosp Clin Res Ctr Chiba Japan;
Chiba Univ Dept Publ Hlth Chiba Japan;
机译:用免疫球蛋白加上西科孢菌素预防川崎病患者冠状动脉异常的疗效预测,预测静脉内免疫球蛋白(KAICA)的风险增加:随机控制,开放标签,盲终点,阶段3 试验(Vol 393,PG 1128,2019)
机译:用免疫球蛋白加上西科孢菌素预防川崎病患者冠状动脉异常的疗效预测,预测静脉内免疫球蛋白(KAICA)的风险增加:随机控制,开放标签,盲终点,阶段3 审判
机译:用免疫球蛋白加上川孢菌素预防川崎病患者冠状动脉异常的疗效预计患者的冠状动脉异常(KAICA研究)的风险增加(KAICA研究):一个受控,第3阶段,随机,开放标签,盲终点试验
机译:川崎病的心率,对静脉免疫球蛋白的反应性和冠状动脉瘤
机译:皮质类固醇添加到初始静脉内免疫球蛋白治疗用于预防高危患者川崎病患者冠状动脉异常
机译:307.用免疫球蛋白加上川孢菌素加冠状动脉异常预测川崎病患者的冠状动脉异常的疗效预计是IVIG非反应的风险增加(KAICA研究):一个受控,第3阶段,随机,开放标签,盲 - 终点试验